Role of aggrecanase 1 in lyme arthritis

Arthritis and Rheumatism

Volumn 54, Issue 10, 2006, Pages 3319-3329

  Behera, Aruna K ^a   Hildebrand, Ethan ^a   Szafranski, Jon ^b   Hung, Han Hwa ^b   Grodzinsky, Alan J ^b   Lafyatis, Robert ^c   Koch, Alisa E ^d   Kalish, Robert ^a   Perides, George ^a   Steere, Allen C ^e   Hu, Linden T ^a,f  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; AGGRECANASE; AGGRECANASE 1; AGGRECANASE 2; COLLAGEN; MATRIX METALLOPROTEINASE; PROTEINASE; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BORRELIA BURGDORFERI; CARTILAGE CELL; CARTILAGE DEGENERATION; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; COW; EXPLANT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; JOINT DESTRUCTION; LYME DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIAL FLUID;

ADAM PROTEINS; ANIMALS; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; CARTILAGE, ARTICULAR; CATTLE; CELLS, CULTURED; CHONDROCYTES; COLLAGEN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LYME DISEASE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; PROCOLLAGEN N-ENDOPEPTIDASE; SYNOVIAL FLUID;

EID: 33750294963     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22128     Document Type: Article

References (37)

1. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987;107:725-31.
2. Steere AC, Duray PH, Butcher EC. Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis: comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum 1988;31:487-95.
3. Hu LT, Eskildsen MA, Masgala C, Steere AC, Arner EC, Pratta MA, et al. Host metalloproteinases in Lyme arthritis. Arthritis Rheum 2001;44:1401-10.
4. Lin B, Kidder JM, Noring R, Steere AC, Klempner MS, Hu LT. Differences in synovial fluid levels of matrix metalloproteinases suggest separate mechanisms of pathogenesis in Lyme arthritis before and after antibiotic treatment. J Infect Dis 2001;184:174-80.
5. Hardingham T, Fosang AJ. Aggrecan, the chondroitin sulphate/keratan sulphate proteoglycan from cartilage. In: Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC, editors. Articular cartilage and osteoarthritis. New York: Raven Press; 1991. p. 5-20.
6. Sandy JD, Neame PJ, Boynton RE, Flannery CR. Catabolism of aggrecan in cartilage explants: identification of a major cleavage site within the interglobular domain. J Biol Chem 1991;266:8683-5.
7. Sandy JD, Boynton RE, Flannery CR. Analysis of the catabolism of aggrecan in cartilage explants by quantitation of peptides from the three globular domains. J Biol Chem 1991;266:8198-205.
8. Ilic MZ, Handley CS, Robinson HC, Mok MT. Mechanism of catabolism of aggrecan by articular cartilage. Arch Biochem Biophys 1992;294:115-22.
9. Loulakis P, Shrikhande A, Davis G, Maniglia CA. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures: putative site(s) of enzymic cleavage. Biochem J 1992;284:589-93.
10. Lark MW, Gordy JT, Weidner JR, Ayala J, Kimura JH, Williams HR, et al. Cell-mediated catabolism of aggrecan: evidence that cleavage at the "aggrecanase" site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain. J Biol Chem 1995;270:2550-6.
11. Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, et al. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 1999;344:61-8.
12. Ilic MZ, Robinson HC, Handley CJ. Characterization of aggrecan retained and lost from the extracellular matrix of articular cartilage: involvement of carboxyl-terminal processing in the catabolism of aggrecan. J Biol Chem 1998;273:17451-8.
13. Sandy JD. A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 2006;14:95-100.
14. Flannery CR, Lark MW, Sandy JD. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan: evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 1992;267:1008-14.
15. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993;36:1214-22.
16. Sandy JD, Flannery CR, Neame PJ, Lohmander LS. The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 1992;89:1512-6.
17. Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001;9:539-52.
18. Behera AK, Hildebrand E, Scagliotti J, Steere AC, Hu LT. Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and murine Lyme arthritis. Infect Immun 2005;73:126-34.
19. Behera AK, Thorpe CM, Kidder JM, Smith W, Hildebrand E, Hu LT. Borrelia burgdorferi-induced expression of matrix metalloproteinases from human chondrocytes requires mitogen-activated protein kinase and Janus kinase/signal transducer and activator of transcription signaling pathways. Infect Immun 2004;72:2864-71.
20. Behera AK, Hildebrand E, Bronson RT, Perides G, Hu LT. MyD88 deficiency results in tissue specific changes in cytokine induction and inflammation in B. burgdorferi infected mice that are IL-18 independent. Infect Immun 2006;74:1462-1470.
21. -ΔΔCt method. Methods 2001;25:402-8.
22. Lin B, Noring R, Steere AC, Klempner MS, Hu LT. Soluble CD14 levels in the serum, synovial fluid, and cerebrospinal fluid of patients with various stages of Lyme disease. J Infect Dis 2000;181:1185-8.
23. Wharton M, Chorba TL, Vogt RL, Morse DL, Buehler JW. Case definitions for public health surveillance. MMWR Recomm Rep 1990;39(RR-13):1-43.
24. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995;44:590-1.
25. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994;330:229-34.
26. Bonassar LJ, Sandy JD, Lark MW, Plaas AH, Frank EH, Grodzinsky AJ. Inhibition of cartilage degradation and changes in physical properties induced by IL-1β and retinoic acid using matrix metalloproteinase inhibitors. Arch Biochem Biophys 1997;344:404-12.
27. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883:173-7.
28. Wang P, Tortorella M, England K, Malfait AM, Thomas G, Arner EC, et al. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (aggrecanase-1) in the trans-Golgi network. J Biol Chem 2004;279:15434-40.
29. Patwari P, Gao G, Lee JH, Grodzinsky AJ, Sandy JD. Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage. Osteoarthritis Cartilage 2005;13:269-77.
30. Sugimoto K, Iizawa T, Harada H, Yamada K, Katsumata M, Takahashi M. Cartilage degradation independent of MMP/aggrecanases. Osteoarthritis Cartilage 2004;12:1006-14.
31. Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, et al. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 2005;16:997-1002.
32. Erlichman C, Adjei AA, Alberts SR, Sloan JA, Goldberg RM, Pitot HC, et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol 2001;12:389-95.
33. Van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, van den Berg WB. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 1999;42:1128-39.
34. Anguita J, Barthold SW, Persinski R, Hedrick MN, Huy CA, Davis RJ, et al. Murine Lyme arthritis development mediated by p38 mitogen-activated protein kinase activity. J Immunol 2002;168:6352-7.
35. Steere AC, Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol 2004;4:143-52.
36. Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, et al. Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem 2003;278:45539-45.
37. Hedlund H, Hedbom E, Heinegard D, Mengarelli-Widholm S, Reinholt FP, Svensson O. Association of the aggrecan keratan sulfate-rich region with collagen in bovine articular cartilage. J Biol Chem 1999;274:5777-81.